Nemaura Medical, Inc. operates as a holding company. The company is headquartered in Manhattan, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients and support obesity and weight-loss programs. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The Company’s applications of its technology include glucose monitoring, temperature monitoring, lactate monitoring, alcohol monitoring, and substance abuse monitoring. Its platform uses precision microsystems-based technology.
최신 재무제표(Form-10K)에 따르면, Nemaura Medical Inc의 총 자산은 $14이며, 순손실입니다.
NMRD의 주요 재무 비율은 무엇인가요?
Nemaura Medical Inc의 유동비율은 0.53이고, 순이익률은 0, 주당 매출은 $0입니다.
Nemaura Medical Inc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Nemaura Medical Inc 주요 수익원은 Aviation Information Technology이며, 최신 수익 발표에서 수익은 4,255,120,598입니다. 지역별로는 China이 Nemaura Medical Inc의 주요 시장이며, 수익은 7,717,136,628입니다.
Nemaura Medical Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Nemaura Medical Inc의 순손실은 $-14입니다.